Analytical Data
-
基因名
NDUFS6
- Application
-
别名
NDUFS6;NADH dehydrogenase [ubiquinone] iron-sulfur Protein 6. mitochondrial
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75380
-
表达区间
28-124aa
-
氨基酸序列
MGSSHHHHHH SSGLVPRGSH MGSFGVRVSP TGEKVTHTGQ VYDDKDYRRI RFVGRQKEVN ENFAIDLIAE QPVSEVETRV IACDGGGGAL GHPKVYINLD KETKTGTCGY CGLQFRQHHH
-
分子量
13 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NDUFS6 is an essential protein component of the mitochondrial respiratory chain complex I, playing a critical role in cellular energy metabolism. Deficiencies in NDUFS6 have been linked to a range of mitochondrial disorders, resulting in impaired ATP production and various clinical manifestations including neurological deficits, myopathy, and cardiomyopathy. The study of NDUFS6 is significant not only for understanding the molecular mechanisms underlying mitochondrial diseases but also for exploring potential therapeutic strategies. Recent advances in recombinant protein technology have enabled researchers to produce NDUFS6 in vitro, facilitating functional studies and investigations into its interactions with other complex I subunits. These studies aim to unravel the structural and functional dynamics of complex I and its assembly processes. Moreover, understanding the pathophysiological effects of NDUFS6 mutations could lead to the development of targeted gene therapies or pharmacological interventions to ameliorate symptoms in affected individuals. As mitochondrial dysfunction is a contributing factor in numerous age-related diseases, research on NDUFS6 could also provide insights into broader aspects of mitochondrial biology and its implications for aging and metabolic health. Overall, the investigation of NDUFS6 and its recombinant forms holds promise for both basic research and the development of novel therapeutic approaches in mitochondrial disease.












